View Market Report Sample to Get CAGR and YOY growth variance analysis
Vendor Landscape
- The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Competitors have to focus on differentiating their product offerings with unique value propositions to strengthen their foothold in the market.
- Market vendors also have to leverage the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
- AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyxone AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor BioPharma Holding Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA are among some of the major market participants.
- Vendors are deploying growth strategies such as aiming at strategic collaborations and acquisitions with other manufacturers to expand their product manufacturing and address the demand of an expanding patient pool to compete in the market.
- To make the most of the opportunities and recover from post pandemic impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
- The rheumatoid arthritis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. Companies such as AbbVie Inc. offers rheumatoid arthritis drug namely Rinvoq.
Buy this report sample now and get strategic insights on the vendors and their product offerings
Rheumatoid Arthritis Drugs Market Segment Highlights
- Type
- Biologics: The biologics segment held the largest rheumatoid arthritis drugs market share in 2021. The segment will continue to account for the highest revenue throughout the forecast period. The growth of the segment is attributed to the promising results of biologics for the complete treatment of RA compared with conventional DMARDs. The patents for some biologics are expected to expire during the forecast period.
- Small Molecules
- Geography
- Europe: 37% of the market's growth will originate from Europe during the forecast period. Germany, UK, and France are the key markets for rheumatoid arthritis drugs in Europe. Market growth in this region will be slower than the growth of the market in the North American and Asian regions. The presence of vendors in the EU, such as Novartis and UCB Pharma will facilitate the rheumatoid arthritis drugs market growth in Europe over the forecast period.
- North America
- Asia
- Rest Of World (ROW)
Get Segment-based Contribution of Each Segment as you Download Report Sample
Rheumatoid Arthritis Drugs Market Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The rheumatoid arthritis drugs market report covers the following areas:
Rheumatoid Arthritis Drugs Market Takeaways
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist rheumatoid arthritis drugs market growth during the next five years
- Estimation of the rheumatoid arthritis drugs market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the rheumatoid arthritis drugs market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of rheumatoid arthritis drugs market, vendors
Related Reports:
POC Molecular Diagnostics Market by Product, Application, and Geography - Forecast and Analysis 2022-2026
Animal Health Diagnostics Market by Type and Geography - Forecast and Analysis 2021-2025
Rheumatoid Arthritis Drugs Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.73% |
Market growth 2022-2026 |
$ 14.90 billion |
Market structure |
Fragmented |
YoY growth (%) |
5.3 |
Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 37% |
Key consumer countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Cyxone AB, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor BioPharma Holding Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 12: Market segments
- 3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between2021 and 2026
- 4.2 Bargaining power of buyers
- Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
- 4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
- 4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
- 4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
- 4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
- 4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
- 5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
- 5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type
- 5.3 Biologics - Market size and forecast 2021-2026
- Exhibit 28: Chart on Biologics - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Biologics - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Biologics - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Biologics - Year-over-year growth 2021-2026 (%)
- 5.4 Small molecules - Market size and forecast 2021-2026
- Exhibit 32: Chart on Small molecules - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Small molecules - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Small molecules - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Small molecules - Year-over-year growth 2021-2026 (%)
- 5.5 Market opportunity by Type
- Exhibit 36: Market opportunity by Type ($ million)
6 Customer Landscape
- 6.1 Customer landscape overview
- Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 38: Chart on Market share by geography 2021-2026 (%)
- Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
- 7.2 Geographic comparison
- Exhibit 40: Chart on Geographic comparison
- Exhibit 41: Data Table on Geographic comparison
- 7.3 Europe - Market size and forecast 2021-2026
- Exhibit 42: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 43: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 44: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 45: Data Table on Europe - Year-over-year growth 2021-2026 (%)
- 7.4 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
- 7.5 Asia - Market size and forecast 2021-2026
- Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
- 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- 7.7 US - Market size and forecast 2021-2026
- Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
- 7.8 Germany - Market size and forecast 2021-2026
- Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
- 7.9 UK - Market size and forecast 2021-2026
- Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
- 7.10 France - Market size and forecast 2021-2026
- Exhibit 70: Chart on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on France - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on France - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on France - Year-over-year growth 2021-2026 (%)
- 7.11 China - Market size and forecast 2021-2026
- Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)
- 7.12 Market opportunity by geography
- Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.3 Impact of drivers and challenges
- Exhibit 79: Impact of drivers and challenges in 2021 and 2026
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
- 9.3 Landscape disruption
- Exhibit 81: Overview on factors of disruption
- 9.4 Industry risks
- Exhibit 82: Impact of key risks on business
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 83: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 84: Matrix on vendor position and classification
- 10.3 AbbVie Inc.
- Exhibit 85: AbbVie Inc. - Overview
- Exhibit 86: AbbVie Inc. - Product / Service
- Exhibit 87: AbbVie Inc. - Key offerings
- 10.4 Amgen Inc.
- Exhibit 88: Amgen Inc. - Overview
- Exhibit 89: Amgen Inc. - Product / Service
- Exhibit 90: Amgen Inc. - Key offerings
- 10.5 Bristol Myers Squibb Co.
- Exhibit 91: Bristol Myers Squibb Co. - Overview
- Exhibit 92: Bristol Myers Squibb Co. - Product / Service
- Exhibit 93: Bristol Myers Squibb Co. - Key offerings
- 10.6 Eli Lilly and Co.
- Exhibit 94: Eli Lilly and Co. - Overview
- Exhibit 95: Eli Lilly and Co. - Product / Service
- Exhibit 96: Eli Lilly and Co. - Key offerings
- 10.7 F. Hoffmann La Roche Ltd.
- Exhibit 97: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 98: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 99: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 100: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 101: F. Hoffmann La Roche Ltd. - Segment focus
- 10.8 Johnson and Johnson
- Exhibit 102: Johnson and Johnson - Overview
- Exhibit 103: Johnson and Johnson - Business segments
- Exhibit 104: Johnson and Johnson - Key news
- Exhibit 105: Johnson and Johnson - Key offerings
- Exhibit 106: Johnson and Johnson - Segment focus
- 10.9 Novartis AG
- Exhibit 107: Novartis AG - Overview
- Exhibit 108: Novartis AG - Business segments
- Exhibit 109: Novartis AG - Key offerings
- Exhibit 110: Novartis AG - Segment focus
- 10.10 Pfizer Inc.
- Exhibit 111: Pfizer Inc. - Overview
- Exhibit 112: Pfizer Inc. - Product / Service
- Exhibit 113: Pfizer Inc. - Key news
- Exhibit 114: Pfizer Inc. - Key offerings
- 10.11 Sanofi
- Exhibit 115: Sanofi - Overview
- Exhibit 116: Sanofi - Business segments
- Exhibit 117: Sanofi - Key news
- Exhibit 118: Sanofi - Key offerings
- Exhibit 119: Sanofi - Segment focus
- 10.12 UCB SA
- Exhibit 120: UCB SA - Overview
- Exhibit 121: UCB SA - Product / Service
- Exhibit 122: UCB SA - Key offerings
11 Appendix
- 11.2 Inclusions and exclusions checklist
- Exhibit 123: Inclusions checklist
- Exhibit 124: Exclusions checklist
- 11.3 Currency conversion rates for US$
- Exhibit 125: Currency conversion rates for US$
- 11.4 Research methodology
- Exhibit 126: Research methodology
- Exhibit 127: Validation techniques employed for market sizing
- Exhibit 128: Information sources
- 11.5 List of abbreviations
- Exhibit 129: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article